Resumen de First in class.
The article reports on negative publicity which Pfizer Inc. has received in 2008 in response to its popular smoking cessation drug Chantix. A discussion of adverse medical and psychological events which have been linked to the drug and reported, and of a decision from the U.S. Federal Aviation Administration to ban the drug's use among its pilots, is presented.
